Prostate Cancer: Preventive Medicine
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 May 2025 to Question 52196 on Prostate Cancer: Preventive Medicine, when he expects to receive the outcome of UK NSCs comprehensive evidence review.
Answered by Ashley Dalton
The UK National Screening Committee (UK NSC) has commissioned work to update its recommendation on population screening for prostate cancer screening last made in 2020. The review this time round however has been expanded in response to calls to consider evidence that looks at targeted screening using prostate-specific antigen testing and other high-risk factors, as well as screening specifically Black men of a set age group and looking at other screening tests. To do this comprehensive review, the UK NSC has commissioned a cost effectiveness model to explore these various screening strategies.
It is expected that the model will report back to the UK NSC in early autumn 2025. The committee is in contact with the reviewers and stands ready to review this and consider next steps before opening a public consultation on this.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →